Citations

Clear

4510 citation(s) found for "Scott, C".

Spatial resolution improvements for photon counting detectors using coincidence counting and frequency weighted reconstruction
Hsieh, Scott S. , Leng, Shuai, McCollough, C, Taguchi, Katsuyuki , Leng, Shuai

Mayo Clinic

Medical Physics | February 6, 2025 | Volume: 52 | Issue: 4 | Pages: 2052-2063

10.1002/mp.17664 | PMID 39912861 Get It

AbstractBackgroundPhoton counting X‐ray detectors (PCDs) provide better spatial resolution than energy integrating X‐ray detectors, but even higher resolution is desired in some applications. Certain charge sharing compensation techniques such as coincidence counting preferentially detect photons that arrive at the boundary between pixels, and this could be used for subpixel localization of incident photons and enhanced spatial resolution.PurposeTo estimate improvements to spatial resolution and detective quantum efficiency that are possible when using coincidence counting for high‐resolution, non‐spectral imaging.MethodsThe modulation transfer function (MTF), noise power spectrum (NPS), and detective quantum efficiency (DQE) were estimated using numerical simulations of a two‐dimensional parallel‐beam CT system. Coincidence counters were modeled either geometrically or with Monte Carlo simulations. The geometric model consisted of narrow coincidence counters that interlaced with wider ordinary pixels, and showed that using standard filtered backprojection decreases low‐frequency DQE, but that a frequency weighting technique could be used to restore DQE. The Monte Carlo simulations were used to estimate the possible improvements that could be expected from real systems. The pixel pitch was 0.25 mm and the source apertures considered were 0, 0.125, and 0.5 mm. A numerical stent phantom was also used to illustrate possible improvements.ResultsAssuming a 0.125 mm source aperture and the Monte Carlo model, the limiting MTF (at 10%) increased from 20 to 40 lp/cm using coincidence counters. This can be explained by the increased sampling (and higher Nyquist limit) possible from coincidence counters. In the geometric model, coincidence counters are compared to conventional double sampling techniques such as in‐plane flying focal spot, and the MTF at 38 lp/cm increased from 5% to 53%. Without the frequency weighting technique, low‐frequency DQE was reduced by about 20%, but these losses are recovered with frequency weighting. Improvements are much more modest with the 0.25 mm source aperture because the system becomes source‐limited.ConclusionsCoincidence counting could be used to increase spatial resolution in PCDs. The increases in system resolution could be large if a high‐resolution X‐ray source were available.
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis
Wood, Cameron , Lyniv, Liliana, Isaacs, James M, Kaufman, Jacob M., Oduah, Eziafa , Clarke, Jeff, Crawford, Jeffrey, Stinchcombe, Thomas E. , Tong, Betty , Wigle, Dennis A. , Dragnev, Konstantin H. , Antonia, Scott , Ready, Neal , Wigle, Dennis, Ready, Neal , Wood, Cameron , Isaacs, James , Wang, Xiaofei , Gu, Lin, Weinhold, Kent J.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | February 4, 2025 | Volume: 13 | Issue: 2 | Pages: e010395

10.1136/jitc-2024-010395 | PMID 39904561 Get It

Background Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. Methods This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, clinical stage IB to IIIA NSCLC. Patients received two doses of 200 mg pembrolizumab, surgery, standard adjuvant chemotherapy, followed by four doses adjuvant pembrolizumab. The primary objective of this study was to determine surgical feasibility rate, and secondary objectives are pathological response rate, treatment adverse events, efficacy data, and exploratory analysis of biomarkers. Results 30 patients initiated perioperative pembrolizumab, and 25 completed tumor resection. At median follow-up of 59 months after surgical resection, seven patients had disease progression, while six had died representing. A 5-year progression-free survival (PFS) from time of surgery was 72.0% (56.4%–91.9%) and overall survival (OS) from time of surgery was 75.8% (60.7%–94.7%). Major pathological response (MPR) was found in seven tumors (28%) including two complete responses (4%). Across all treated patients, four receiving neoadjuvant and four receiving adjuvant pembrolizumab experienced treatment-related adverse events of grade 3 or higher with no grade 5 events. Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels increased across our patient cohort over time from baseline until postsurgery and remained elevated at the end of treatment. There was a significant difference between mean plasma PCSK9 levels for patients with MPR versus all other patients on study when checked postoperatively. Conclusions Perioperative pembrolizumab was safe and effective with promising MPR rate, PFS, and OS.
Photon Counting Detector CTA for Prostate Artery Embolization Pre-Procedure Planning and Intra-Procedural Guidance: A Case Series
Yousif, Paul , Linch, Forrest , Favazza, Christopher , Ferrero, Andrea , Jundt, Michael C., Linch, Forrest B , Yousif, Paul, Rajiah, Prabhakar , Collins, Jeremy D. , Thompson, Scott M.

Mayo Clinic

No container title available | February 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5898895/v1 Get It

Abstract Background: Prostate artery embolization (PAE) requires a careful understanding of pelvic arterial anatomy and identifying prostatic artery variants. Pre-procedure CTA and intra-procedural cone beam CT are traditional means of planning and performing PAE, with the latter providing guidance for embolization. Photon counting detector (PCD) CT is a novel technology enabling ultra-high spatial resolution (UHR) whole-body imaging, with reconstructed slices as thin as 200 um. For PAE, we obtain a single UHR PCD CT acquisition, which provides both detailed pre-procedure pelvic arterial anatomy information and a registration reference for intra-procedural embolization guidance. Case Presentation: In five patients who underwent technically successful PAE via a left transradial approach, the pre-procedure diagnostic UHR PCD prostate CTA delineated bilateral prostatic artery origins and course in all cases, as confirmed with conventional angiograms. Further, registration of the UHR PCD CT for embolization guidance was successful in all cases, augmenting vessel selection. No complication occurred. Conclusion: UHR PCD CT is a novel acquisition option that is well suited to PAE due to its ability to delineate small vessels. Further, our experience has shown that a single pre-procedure scan can also be utilized for intra-procedural embolization guidance, obviating the need for a traditional cone beam CT angiogram. Further research is needed to assess reductions in radiation dose, contrast use, and intra-procedural time with these techniques.
Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis
Zorman, Mark , Vibhishanan, Jonathan , Dangas, Katerina, Castle, James , Li, Ka Hou Christien , Coronelli, Marco , Eastwick-Jones, Kate , Swan, Alexander, Johnson, N M, Choksey, Anurag , Scott, Sam G.C., Henry, Matthew , Cassar, Mark Philip , Barnes, C. , Ferreira‐Martins, João , Newton, James D. , Alkhouli, Mohamad , Rihal, Charanjit S. , Eleid, Mackram F. , Zorman, Mark J , Newton, James , Dawkins, Sam , Rihal, Charanjit, Eleid, Mackram F , Sabbah, Michael S. , Swan, Alexander, Johnson, Nicky, Yan, Helen H.N. , Barnes, Cara, Alkhouli, Mohamad , Rihal, Charanjit S. , Pislaru, Sorin V. , Guerrero, Mayra , Ordóñez-Mena, José Manuel , Cahill, Thomas J.

Mayo Clinic

European Heart Journal - Cardiovascular Pharmacotherapy | February 2, 2025 | Volume: 11 | Issue: 3 | Pages: 251-263

10.1093/ehjcvp/pvaf005 | PMID 39904549 Get It

Abstract Aims Transcatheter mitral valve replacement (TMVR) has become a feasible alternative to surgical mitral valve replacement (SMVR) in selected patients at high surgical risk. The risk of valve thrombosis following SMVR and TMVR, and the optimal antithrombotic therapy following these procedures, remains uncertain. We aimed to compare the incidence of bioprosthetic mitral valve thrombosis (bMVT) after SMVR and TMVR, and the incidence of bMVT between patients on different antithrombotic regimens. Methods and results A literature search of Medline, Embase, and Cochrane Library was performed between January 2000 and August 2024. Random-effects models were used to derive pooled estimates of the incidence of bMVT in the absence of prior or active endocarditis and valve thrombosis. A total of 47 studies (6170 patients, total follow-up 9541.8 patient-years) were eligible for inclusion. The overall incidence of bMVT was 5.05 [95% confidence interval (CI) 3.18–8.01, I2 = 82%] per 100-patient-years. Subclinical bMVT was more common than clinically significant bMVT: incidence 19.11 vs. 7.91 per 100-patient-years, adjusted incidence rate ratio (aIRR) 4.62 (95% CI 1.39–15.36), P = 0.012. bMVT was numerically more common after TMVR than SMVR, but the comparison was not statistically significant: incidence 7.03 vs. 0.58 per 100-patient-years, aIRR 2.19 (95% CI 0.72–6.72), P = 0.170. Patients on vitamin-K antagonists (VKA) had a lower incidence of bMVT than patients on direct oral anticoagulants (DOAC; incidence 5.72 vs. 17.08, aIRR 0.31, 95% CI 0.13–0.73, P = 0.007). Conclusions bMVT is not uncommon, with numerically higher incidence in transcatheter compared to surgical valves, but the comparison was not statistically significant. VKAs are associated with a lower incidence of bMVT compared to DOACs.
Absorption of naloxone in patients prescribed buprenorphine‐naloxone
Michel, Ian , Ochal, Domenic , Paharia, Aniket, Jannetto, Paul J. , Breitinger, Scott , Oesterle, Tyler , Jannetto, Paul, Oesterle, Tyler S

Mayo Clinic

The American Journal on Addictions | February 2, 2025 | Volume: 34 | Issue: 3 | Pages: 350-354

10.1111/ajad.13674 | PMID 39893563 Get It

AbstractBackground and ObjectivesWhen administered as prescribed, the naloxone component of buprenorphine‐naloxone combination medications is putatively considered inert due to reduced naloxone bioavailability via transmucosal. However, there is a growing body of evidence to the contrary. The aim of our study is to determine the extent of naloxone absorption in a large cohort of patients receiving sublingual buprenorphine‐naloxone.MethodsUsing the Mayo Clinic Unified Data Platform, 425 patients prescribed sublingual buprenorphine/naloxone who received a controlled substance monitoring panel (CSMP) between January 1, 2022, and January 1, 2023 were identified and included. The CSMP is an immunoassay panel that confirms positive results quantitatively with gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry. This panel provides urinary detection for buprenorphine (cutoff: 5 ng/mL), naloxone (25 ng/mL), as well as their respective metabolites norbuprenorphine (5 ng/mL), norbuprenorphine‐glucuronide (20 ng/mL), and naloxone‐glucuronide (100 ng/mL).ResultsOf our 425 patients, 76% had norbuprenorphine (n = 323), and 77% had norbuprenorphine‐glucuronide (n = 327) in their toxicology tests, respectively. Naloxone‐glucuronide was detected in 91% (n = 294) of the specimens with norbuprenorphine and 88.7% (n = 290) of the specimens with norbuprenorphine‐glucuronide.Conclusion and Scientific SignificanceTo our knowledge, this is the largest study to date demonstrating the presence of naloxone metabolites in patients taking combined buprenorphine‐naloxone medications. The results of this study refute the notion that naloxone absorption is negligible when administered in sublingual preparations. Further research on how this absorption impacts medication usage, dosing, adherence, and side effects is necessary.
204: RHYTHM AND BLUES: A CASE REPORT ON CARDIAC ARRHYTHMIAS SECONDARY TO PROPOFOL INFUSION SYNDROME
Fashina, Oluwatomini, McKone, Justin, Anjewierden, Scott , Arteaga, Grace M.

Mayo Clinic

Critical Care Medicine | January 31, 2025 | Volume: 53 | Issue: 1 | Pages: No page available

10.1097/01.ccm.0001099480.10745.17 Get It

Heart failure with preserved ejection fraction: incidence and impact on mortality in patients with secondary tricuspid regurgitation
Anand, Vidhu , Singh, Sumitabh , Pugliesi, G, Scott, Christopher G. , Pislaru, Sorin V. , Nkomo, Vuyisile T. , Borlaug, Barry A.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 29, 2025 | Volume: 26 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjci/jeae333.066 Get It

Abstract Introduction Secondary tricuspid regurgitation (STR) is a highly prevalent valve disease. STR and Heart Failure with preserved Ejection Fraction (HFpEF) share common features including exertional intolerance and high burden of atrial fibrillation (AF) and pulmonary hypertension (PH), making it challenging to disentangle HFpEF from TR. The incidence of clinically-recognized HFpEF in STR and its impact on mortality are not well established. Purposes To define the incidence of newly diagnosed HFpEF and its impact on mortality in a cohort of patients with significant STR and to evaluate the likelihood of a larger hidden burden of HFpEF. Methods Patients with a first diagnosis of ≥moderate-severe STR between 2004-2019 at our institution were retrospectively included. Patients with left ventricle ejection fraction <50%, left-sided valve diseases, and intracardiac device leads were excluded. HFpEF was identified by manual chart review as well as by use of ICD codes. The estimated prevalence of HFpEF was evaluated using an H2FPEF score ≥6, which corresponds to a ≥90% probability of having HFpEF. Results Of 2118 patients (mean age 70 ± 14, 36% females), 1057 (50%) had systemic hypertension (HTN) and 1091 (51%) had AF, with median 2.3 years of follow-up. From this cohort, 536 (25%) patients were diagnosed with HFpEF based upon chart review during the follow up period, while ICD diagnosis was only present in fewer than 50% of these patients (254). High H2FPEF score was present in 880 patients (41.5%), of whom 383 received a chart diagnosis of HFpEF, while 153 patients with H2FPEF score <6 received a chart HFpEF diagnosis. The cumulative incidence of chart-based diagnosis of HFpEF was 20.8% (N=158) at 1-year and 38.6% (N=273) at 5-years in patients with an H2FPEF score ≥6 and 5.5%(N=60) at 1-year and 11.1%(N=111) at 5-years in those with a score <6 (Figure). In Cox regression analyses, the diagnosis of HFpEF during follow-up was associated with increased mortality (HR 2.14, CI 1.86-2.46, p < 0.001) after adjusting for age, sex, body mass index, coronary artery disease, diabetes mellitus, chronic obstructive pulmonary disease, diuretics, HTN, pulmonary hypertension, chronic kidney disease and AF. Conclusions The incidence of clinically documented HFpEF in a cohort of patients with significant STR at index evaluation is high (25%). Use of ICD code underestimates clinical recognition, with the actual burden of HFpEF probably being even greater, as indicated by an H2FPEF score ≥ 6. Among those with significant STR, HFpEF diagnosis is an independent risk factor for mortality.
Guideline adherence to echocardiographic monitoring of aortic stenosis
Gochanour, Benjamin R. , Thaden, Jeremy J. , Donisan, Teodora , Balanescu, Dinu Valentin , Scott, Christopher G. , Pislaru, Sorin V. , Nkomo, Vuyisile T. , Kane, Garvan C.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 29, 2025 | Volume: 26 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjci/jeae333.167 Get It

Abstract Background/Introduction Close monitoring of aortic stenosis (AS) by follow-up echocardiography is recommended by all Cardiology and Imaging Societies’ guidelines. Whether these guidelines are strictly followed is unknown. Purpose We aimed to describe our institution’s practice patterns for echocardiographic monitoring in patients with aortic sclerosis (AScl) and AS of any severity. Methods Adult patients residing in our institution’s county with an echocardiographic diagnosis of AScl or AS between 01/2005-01/2022 were identified and classified into 4 groups: AScl, mild AS, moderate AS, or severe AS, at each echocardiogram during the study timeframe. Kaplan Meier analyses were used to evaluate the composite outcome, the occurrence of follow-up echocardiogram or death. Patients were censored at the time of aortic valve replacement/repair, heart transplant, or last clinical follow-up. Guideline follow-up was considered appropriate when the primary outcome occurred by 5 years (AScl/mild AS), 2 years (moderate AS), and 1 year (severe AS). Results A total of 23,726 echocardiograms from 9,578 unique patients were included. At index echocardiogram, median patient age was 74 years (IQR 65-82) and 4,806 (50.2%) were women. AScl was observed in 7,358 (76.8%) cases, mild AS in 1,442 (15.1%) cases, moderate AS in 479 (5%), and severe AS in 301 (3.1%) cases. Rates of composite outcome achievement by the end of the guideline-recommended interval were 81%, 90%, 80%, and 72% in AScl, mild, moderate, and severe AS, respectively. Rates for men were 83%, 92%, 82%, and 75% in these groups, while rates for women were 78%, 88%, 78%, and 68%, respectively (Figure 1). Follow-up rates were similar before and after 2012 (when transcatheter aortic valve replacement was approved for treatment of severe AS in high-risk surgical patients in the USA). Follow-up rates were higher in patients managed by cardiovascular providers compared to non-cardiovascular providers (Figure 2). Conclusion Depending on disease severity, between one fourth and one tenth of patients remained alive and unfollowed at the end of their guideline-recommended surveillance interval. There is significant variability in echocardiogram monitoring based on sex and referring provider specialty. Figure 1 Figure 2
Surgical intervention patterns and long-term survival of bicuspid aortic valve patients: community-based versus tertiary-referral cohorts
Tsaban, Gal , Hernandez, M A Montoya, Scott, Christopher G. , Pislaru, Sorin V. , Enriquez‐Sarano, Maurice , Michelena, Héctor I.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 29, 2025 | Volume: 26 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjci/jeae333.141 Get It

Abstract Background Bicuspid aortic valve(BAV) disease carries a cumulative lifetime morbidity >80%. This morbidity includes surgery for aortic valve dysfunction, aortic dilatation, infective endocarditis, and aortic dissection. This study assessed surgical intervention patterns for BAV-related morbidity and long-term survival of these patients in a community-based cohort versus a tertiary referral cohort. Methods The tertiary-referral cohort included all patients with BAV-related surgeries across Mayo Clinic sites (Arizona, Florida, and Minnesota), from January 1990 to May 2024. The community-based cohort included all patients with BAV-related surgeries in Olmsted County, Minnesota, from January 1980 to May 2024. The tertiary-referral cohort comprised 2529 BAV patients of which 991(39%) [mean age 53±15 years, 76% males] underwent aortic valve surgery(AVR), aorta surgery, or a combination thereof, while the community-based cohort included 652 BAV patients of whom 262(40%) [mean age 43±20 year, 70% males] had the mentioned interventions. Cumulative survival was calculated by Kaplan-Meier method compared to the U.S population. Statistical significance was evaluated using one-sample log rank statistics. Results In the tertiary-referral cohort, 530/991(54%) patients underwent isolated AVR, 62/991(6%) had isolated aortic surgery, and 399(40%) underwent combined procedures. In the community-based cohort, 179/262(68%) patients underwent isolated AVR, 30/262(11%) underwent isolated aortic surgery, and 53(21%) had combined surgeries. In the tertiary-referral cohort, 940 patients underwent AVR; 57% for aortic stenosis(AS), 29% for aortic regurgitation(AR), 13% for mixed valvular disease, and 1% for endocarditis. In comparison, in the community-based cohort, 236 patients underwent AVR for AS in 71%, AR 20%, mixed valvular disease 7%, and endocarditis 2%. In the tertiary-referral cohort, 459 patients underwent aortic surgery; 21% for the root, 69% for the ascending aorta, 1% for the arch, <1% for aortic dissection, and 8% for coarctation repair. In comparison, 105 patients from the community-based cohort underwent aortic surgery; 33% for the root, 44% for the ascending aorta, 1% for the arch, 4% for aortic dissection and 18% coarctation repair. Compared to age- and sex-matched U.S. population, the relative risk for all cause death in the tertiary-referral cohort was 0.89 [95% CI: 0.70-1.11, p=0.35], whereas in the community-based cohort was 1.06 [95% CI: 0.85-1.32, p=0.57](Figure1). Conclusion Surgical intervention patterns were similar for community and tertiary BAV cohorts, with most patients undergoing isolated AVR or AVR plus aortic surgery, and isolated aortic surgery being uncommon. AVR indications were driven by AS, followed by AR and mixed valvular disease. Aortic surgery indications were driven by ascending aorta dilatation, followed by root dilatation and coarctation. Survival in both cohorts was similar to the U.S. general population.
Pulmonary artery effective elastance in patients with tricuspid valve regurgitation: a simple effective echo marker for risk stratification
Kane, Christopher , Anand, Vidhu , Padang, Ratnasari , Bird, Jared, Thaden, Jeremy J. , Kane, C, Naser, J A, Lara-Breitinger, Kyla M , Nkomo, Vuyisile T. , Kane, Garvan C. , Pislaru, Cristina , Scott, Christopher G. , Pislaru, Sorin V.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 29, 2025 | Volume: 26 | Issue: Supplement_1 | Pages: No page available

10.1093/ehjci/jeae333.142 Get It

Abstract Background/Introduction Tricuspid valve regurgitation (TR) is a common valvular disease associated with increased mortality. There is a need for tools to assess the interaction between the pulmonary artery (PA) circulation and the right ventricle (RV) in patients with TR and to investigate their association with outcomes. Various echo parameters have emerged that assess RV-PA coupling, including the ratio of TAPSE to RV systolic pressure (RVSP) and the PA pulsatility index (PAPi). The effective PA elastance (PA Ea) is a composite measure of RV afterload that refers to the measure of the pulmonary vascular load that the RV must overcome to eject blood into the PA. PA Ea is simple to estimate by echo and found to be an independent haemodynamic risk measure in various left heart and pulmonary hypertension (PH) diseases. Whether PA Ea discriminates risk in unselected patients with significant TR and how it compares to other measures of RV-PA coupling is untested. Purpose To ascertain the prognostic value of PA Ea in patients with TR. Methods In consecutive patients with a first diagnosis of ≥ moderate TR (regardless of aetiology), we compared all-cause mortality at five years based on the PA Ea (defined as the RVSP/stroke volume as measured by transthoracic echocardiography). As stroke volume was measured by Doppler at the left ventricular (LV) outflow tract, patients with > moderate aortic valve regurgitation were excluded. The Tricuspid Regurgitation Impact on Outcomes (TRIO) score was calculated as previously described. PA Ea was separated into 4 groups for comparison based on the separation of quartiles of PA Ea rounded to one decimal place. Results In the 13,608 patients studied, PA Ea could be calculated in 12,682 patients (94.4%). The median PA Ea was 0.68 mmHg/mL (IQR 0.50, 0.92). Increasing levels of PA Ea were associated with clinical comorbidities including heart failure, liver and kidney disease and clinical markers of risk such as the TRIO score. Increasing levels of PA Ea were also associated with larger RVs, worse RV systolic function, higher NT-pro BNP levels, and greater degrees of right heart failure (Table). Each quartile of PA Ea was associated with a significant increase in all-cause mortality (Figure). After adjusting for age and sex, PA Ea was associated with higher risk of death (HR 2.41 (2.28-2.56); p<.0001). While worsening degrees of PA Ea correlated with both declining levels of TAPSE/PASP and PAPi (Table), PA Ea was independently predictive of outcome in a combined model: PA Ea HR 1.65 (1.51-1.80, Chi-squ 120, p<.0001); PAPi HR 0.84 (0.80-0.89, Chi-squ 48, p<.0001) and TAPSE/PASP HR 0.32 (017-0.60, Chi-squ 12, p=.0004). Conclusion(s) In patients with significant TR, PA Ea is highly feasible and higher PA Ea is progressively associated with RV dysfunction, right heart failure, and worse survival. Incorporating PA Ea into the routine echo assessment may help stratify disease severity in patients with significant TR. Table Assoc. of PA Ea with mortality in TR